NERV

Business Context and Reporting Period

Company: Minerva Neurosciences, Inc. (NERV)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Minerva is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) diseases. Its lead product candidate, roluperidone, is in development for the treatment of negative symptoms in schizophrenia. The company has no approved products and has not generated product revenue.

Key Financial Metrics

Note: The 2025 net loss includes a non-cash loss of $321.5 million related to the issuance of convertible preferred stock and warrants, partially offset by a $45.4 million non-cash gain from changes in the fair value of warrant liability.

Material Changes vs. Prior Period

• Financing Activity: In October 2025, the company completed a private placement of Series A Convertible Preferred Stock and warrants, receiving gross proceeds of $80.0 million (net proceeds approx. $74.3 million). This significantly increased cash reserves from $21.5 million in 2024 to $82.4 million in 2025.
• Operating Expenses: Total operating expenses decreased by approximately $6.7 million year-over-year, driven primarily by a reduction in Research and Development (R&D) expenses from $11.9 million to $5.8 million. This decrease was attributed to the absence of drug substance validation campaign costs and lower consultant fees in 2025 compared to 2024.
• Non-GAAP Adjusted Net Loss: Excluding non-cash items (stock-based compensation, warrant liability changes, and issuance losses), the adjusted net loss narrowed from $(19.3) million in 2024 to $(16.0) million in 2025.
• Share Count: Following the conversion of a portion of the Series A Preferred Stock in December 2025, common shares outstanding increased to approximately 43.3 million.

Guidance, Outlook, and Risks

Clinical Development Outlook

• Roluperidone (C19 Trial): Following a Complete Response Letter (CRL) from the FDA in February 2024 regarding the initial NDA, the company has aligned with the FDA on the design of a new Phase 3 confirmatory trial (C19).
  • Timeline: First patient screened is expected in Q2 2026.
  • Results: Topline efficacy results are expected in H2 2027; relapse assessment data in H2 2028.
  • Design: 380 patients, 12-week primary endpoint, followed by a 40-week relapse assessment.
• Seltorexant: The company sold royalty rights to Royalty Pharma in 2021 for $60 million upfront plus potential milestones. Janssen is currently recruiting for a Phase 3 trial. No further financial obligations exist to Janssen.

Liquidity and Capital Resources

Management believes the $82.4 million in cash on hand is sufficient to meet operating commitments for at least 12 months from the filing date. The company expects to continue incurring net losses and negative cash flows from operations for the foreseeable future as it advances the C19 trial.

Key Risks

• Regulatory Uncertainty: Success is highly dependent on the C19 trial results. Failure to meet endpoints or delays could materially harm the business.
• Capital Requirements: Additional capital will be required to fund the C19 trial and potential commercialization. Future financing may result in significant dilution.
• Warrant Liability: The company has recorded a significant warrant liability ($171.5 million as of Dec 31, 2025) which is subject to fair value remeasurement, creating volatility in reported earnings.
• Competition: The market for schizophrenia treatments is competitive, with new entrants like Cobenfy (Karuna/BMS) recently approved.

Investor Verification Checklist

• C19 Trial Initiation: Verify the actual start date of the C19 Phase 3 confirmatory trial against the Q2 2026 guidance.
• Warrant Liability Valuation: Review the assumptions used for the fair value of the warrant liability (probability of milestone achievement, volatility) as these significantly impact reported net income.
• Cash Burn Rate: Monitor quarterly cash burn to ensure the 12-month liquidity runway remains valid given the upcoming costs of the C19 trial.
• Series A Conversion: Track the conversion of remaining Series A Preferred Stock and the exercise of Tranche A and B warrants, which could lead to substantial dilution.
• Seltorexant Milestones: Monitor Janssen's Phase 3 progress for seltorexant to assess the likelihood of receiving the remaining $95 million in potential milestone payments from Royalty Pharma.